3-(吡啶-4-基)苯甲腈 | 4350-55-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(吡啶-4-基)苯甲腈
• 英文名称: 3-(4-pyridyl)benzonitrile
• 英文别名: 3-(pyridin-4-yl)benzonitrile；4-(3-cyanophenyl)-pyridine；3-pyridin-4-ylbenzonitrile
• CAS: 4350-55-4
• 化学式: C₁₂H₈N₂
• mdl: MFCD06801941
• 分子量: 180.209
• InChiKey: OGSJPFDYGHOODD-UHFFFAOYSA-N

物化性质

• 沸点：
  336.4±25.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(吡啶-4-基)苯甲腈 在 盐酸 、 aluminum (III) chloride 、 lithium aluminium deuteride 、 platinum on carbon 、 氢气 、 碳酸氢钠 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 20.0~50.0 ℃ 、3.0 MPa 条件下， 反应 9.5h， 生成
  参考文献：
  名称：

  Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638

  摘要：

  Replacing hydrogen with deuterium as a means of altering ADME properties of drug molecules has recently enjoyed a renaissance, such that at least two deuterated chemical entities are currently in clinical development. Although most research in this area aims to increase the metabolic stability, and hence half-life of the active species, experience has shown that prediction of the in vivo behaviour of deuterated molecules is difficult and depends on multiple factors including the complexity of the metabolic scheme, the enzymes involved and hence the mechanism of the rate-determining step in the biotransformation. In an effort to elucidate some of these factors we examined the metabolic behaviour of two molecules from the Sanofi portfolio in a range of in vitro and in vivo systems. Although some key metabolic reactions of the acetylcholine release stimulator HP184 4 were slowed in vitro and in vivo when deuterium was present at the sites of metabolism, this did not translate to an increase in overall metabolic stability. By contrast, the tryptase inhibitor AVE5638 13 was much more metabolically stable in vitro in its deuterated form than when unlabelled. These results indicate that it could be of value to concentrate efforts in this area to molecules which are metabolised by a major pathway that involves enzymes of the amine oxidase family or other low-capacity enzyme families. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.03.065

文献信息

• Process for the preparation of tryptase inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1571150A1

  公开（公告）日：2005-09-07

  This invention is directed to processes for the preparation of compounds of the formula I and their salts, which are useful as tryptase inhibitors, to intermediates useful in the preparation of such compounds, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such compounds.

  该发明涉及制备式I化合物及其盐的过程，这些化合物可用作曲激酶抑制剂，还涉及制备这些化合物的有用中间体、制备这些中间体的过程，以及利用这些中间体制备这些化合物的用途。
• Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
  申请人：Mallams K. Alan

  公开号：US20070066621A1

  公开（公告）日：2007-03-22

  In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种形式中，本发明提供了一类新颖的吡唑并[1,5-a]吡啶，吡唑并[1,5-c]嘧啶和2H-吲唑化合物的4-氰基，4-氨基和4-氨基甲基衍生物，以及咪唑并[1,2-a]吡啶和咪唑并[1,5-a]吡嗪化合物的5-氰基，5-氨基和5-氨基甲基衍生物作为细胞周期依赖性激酶的抑制剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种此类化合物的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
• Bipyridine compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04968804A1

  公开（公告）日：1990-11-06

  Compounds of formula I ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, Y, Z and R.sub.1 -R.sub.4 are as defined in the description, have valuable pharmaceutical properties and are especially active against tumours. They are prepared in a manner known per se.

  式I的化合物，其中X.sub.1，X.sub.2，X.sub.3，X.sub.4，X.sub.5，X.sub.6，Y，Z和R.sub.1 -R.sub.4如描述中所定义，具有有价值的药物性质，特别对抗肿瘤活性强。它们以已知的方式制备。
• [EN] SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] DIHYDROPYRIMIDINONES BICYCLIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE L'ÉLASTASE NEUTROPHILE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016016364A1

  公开（公告）日：2016-02-04

  This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及公式1的取代双环二氢嘧啶酮，并将其用作中性粒细胞弹性蛋白酶活性的抑制剂，包含它们的制药组合物以及将它们用作治疗和/或预防肺部，胃肠道和泌尿系统疾病，皮肤和眼部炎症性疾病以及其他自身免疫和过敏性疾病，移植排斥和肿瘤性疾病的药物的方法。
• Biaryl compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05064832A1

  公开（公告）日：1991-11-12

  Compounds of formula I ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, Y, Z and R.sub.1 -R.sub.4 are as defined in the description, have valuable pharmaceutical properties and are especially active against tumors. They are prepared in a manner known per se.

  公式为I的化合物，其中X.sub.1，X.sub.2，X.sub.3，X.sub.4，X.sub.5，X.sub.6，Y，Z和R.sub.1-R.sub.4的定义如描述中所述，具有有价值的药物特性，特别是对肿瘤具有高活性。它们以已知的方式制备。